34
Participants
Start Date
August 16, 2021
Primary Completion Date
May 31, 2025
Study Completion Date
May 31, 2025
Mogamulizumab
"For the first 28-day induction cycle (C1), mogamulizumab 1 mg/kg will be administered as an IV infusion through a 0.22- or 0.2-μm in-line filter over at least 60 minutes on Days 1, 8, 15, and 22.~For all subsequent 28-day cycles (C2, 3, 4, etc.), mogamulizumab 2 mg/kg will be administered as an IV infusion over at least 60 minutes on Day 1 of each subsequent therapy cycle."
New York Presbyterian Hospital, New York
University of Pittsburgh School of Medicine, Pittsburgh
Tulane University School of Medicine, New Orleans
MD Anderson Cancer Center, Houston
City of Hope National Medical Center, Duarte
University of California Irvine, Irvine
Stanford Cancer Center, Stanford
Hôpital Saint Louis, Paris
Azienda Ospedaliera Città della Salute e della Scienza di Torino, Turin
Hospital del Mar, Barcelona
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario Fundacion Jimenez Diaz, Madrid
Hospital Universitario De Salamanca, Salamanca
Queen Elizabeth Hospital, Birmingham
Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital, London
The Christie NHS Foundation Trust, Manchester
Lead Sponsor
Kyowa Kirin, Inc.
INDUSTRY